The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma

home / insights / the-role-of-tyrosine-kinase-inhibitors-in-unresectable-hepatocellular-carcinoma

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss the role of tyrosine kinase inhibitors in unresectable hepatocellular carcinoma, second-line treatment options, and recent clinical trials.

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma

EP. 1: Examining the Role of Liver Function in HCC

Richard Finn, MD;David James Pinato, MD, MRCP, PhD
April 16th 2024

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss driving forces for the development of hepatocellular carcinoma, including different types of viral hepatitis and non-alcoholic steatohepatitis.

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma

EP. 2: HCC Staging: Improving Treatment Strategies

Richard Finn, MD;David James Pinato, MD, MRCP, PhD
April 16th 2024

The key opinion leaders discuss staging systems they use in clinical practice and their effectiveness in creating treatment algorithms, particularly with respect to Child-Pugh scores.

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma

EP. 3: Locoregional Therapies for Intermediate-Stage HCC

Richard Finn, MD;David James Pinato, MD, MRCP, PhD
April 23rd 2024

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, review locoregional therapies for hepatocellular carcinoma, including transarterial chemoembolization (TACE) and radioembolization.

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma

EP. 4: HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

Richard Finn, MD;David James Pinato, MD, MRCP, PhD
April 23rd 2024

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.